Gene Therapy Book by MDA Grantee

'Muscle Gene Therapy' brings together the latest research in this promising field 

Article Highlights:
  • Dongsheng Duan has published a new book on the latest advances in gene therapy for muscle disease.
  • Strategies such as exon skipping, RNA interference and gene transfer are described.
  • Dongsheng Duan, who has received MDA funding for gene therapy research, directed the book at researchers and academics, but it may interest lay readers as well. 
by Miriam Davidson on March 8, 2010 - 11:19am

-A +A

MDA grantee Dongsheng Duan has published a book on the latest advances in gene therapy for muscle disease, particularly muscular dystrophies.

Duan, a professor of microbiology and immunology at the University of Missouri, served as editor of the book Muscle Gene Therapy and co-authored two of its 15 chapters. Duan is currently researching gene transfer therapy in dogs.

About the new book

Muscle Gene Therapy brings together work by numerous current and former MDA research grantees who are experts in the fields of muscle gene modification, augmentation and transfer.

Several chapters address the promise of exon skipping, a process to repair the defective gene which has proven effective in animal models and is now being tried in boys with Duchenne muscular dystrophy (DMD). Other chapters examine RNA interference, stem cell therapies, and the development and application of the muscle gene delivery vehicle known as adeno-associated viral vector, or AAV.

The book looks at special issues, including gene therapy for cardiac and respiratory muscles and gene therapy directed at babies in the womb. It also examines the bumpy road that clinical gene therapy has traveled and finds that, despite the setbacks, “muscle gene therapy has finally come of age.”

In addition to editing the book and writing the prologue, Duan co-authored chapters on Duchenne cardiomyopathy gene therapy and delivery of large therapeutic genes. Another current MDA grantee, Jeffrey Chamberlain of the University of Washington, Seattle, co-authored a chapter on systemic gene delivery.

Other contributors who have received MDA support include Barry Byrne of the University of Florida in Gainesville; Paul Gregorevic of the Baker IDI Heart & Diabetes Institute in Melbourne, Australia; Xiao Xiao of the University of North Carolina-Chapel Hill; Paula Clemens of the University of Pittsburgh; and Qi Long Lu of Carolinas Medical Center in Charlotte, N.C.

Although Muscle Gene Therapy is directed at researchers and academics, it may interest patients, families and caregivers wishing to learn more about this promising but complex field. Published by Springer in January, it is available for $179, online or in book stores.

Your rating: None Average: 4.3 (6 votes)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or e-mail publications@mdausa.org. See comment policy

NEW YORK., March 16, 2010

NEW YORK., March 16, 2010 Stem Cell Cures Any Closer? Where America Stands: New Problems and Solutions as Stem Cell Research Finally Picks Up Steam http://tinyurl.com/ydr6zcu

Good to see a complete muscle

Good to see a complete muscle gene therapy book. I just red a news about vitro model to study human muscle physiopathology http://www.rsc.org/Publishing/Journals/cb/Volume/2010/03/micro_engineering.asp

OUTH SAN FRANCISCO,

OUTH SAN FRANCISCO, CA--(Marketwire - 03/10/10) - Cytokinetics, Incorporated (NASDAQ:CYTK - News) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease. CK-2017357 is the lead drug candidate that has emerged from the company's skeletal sarcomere activator program. Cytokinetics plans to initiate a Phase II Evidence of Effect clinical trial for CK-2017357 in ALS patients in the first half of 2010. "We are pleased that the FDA has granted orphan drug status to CK-2017357 for the potential treatment of ALS. This designation indicates their recognition that this novel drug candidate may address significant unmet medical needs in patients suffering from this grievous and uniformly fatal disease," said Andrew A. Wolff, M.D, Senior Vice President and Chief Medical Officer of Cytokinetics. "With the planned initiation of our Phase II Evidence of Effect trial in patients with ALS, we look forward to continuing to work closely with regulators, as well as with our clinical investigators and key opinion leaders in the field of ALS, to advance this promising drug candidate through clinical development." http://tinyurl.com/yk4shxt

Interesting interview on stem

Interesting interview on stem cells March 9th, 2010 Dr. George Daley: Stem Cell Research The arguments will be made that now that we have IPS cells and we have adult stem cells, we no longer need embryonic stem cells. Scientists who study these cells don’t agree. There are many questions that remain unanswered about the behavior of IPS cells. Will they be the same as embryonic stem cells? Will they behave in a safe and productive matter? We know that already that adult stem cells don’t give us the same versitility as embryonic or IPS. So I would say, as a scientist and as a physician, it’s far too early to be closing any doors of opportunity. If we want to understand disease, if we want to push the frontiers of medical knowledge, we need all the tools available to us. http://tinyurl.com/yafzj3y Bookmark this site: Not related to md but child was cured in 2 years for blood disorder..interesting http://stemcell.childrenshospital.org/
Feedback Form
Feedback Analytics